{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(3)"],"submitter":["Schonfeld SJ"],"pubmed_abstract":["<h4>Importance</h4>Immune checkpoint inhibitors (ICIs) have improved survival in patients with advanced melanoma but can be associated with a spectrum of immune-related adverse events (AEs), including both autoimmune-related AEs and other immune-related inflammatory AEs. These associations have primarily been evaluated in clinical trials that include highly selected patients, with older adults often underrepresented.<h4>Objective</h4>To evaluate the association between use of ICIs and immune-related AEs (autoimmune and other immune related) among older patients with cutaneous melanoma.<h4>Design, setting, and participants</h4>A population-based cohort study was conducted from January 1, 2011, to December 31, 2015. Data were analyzed from January 31 to May 31, 2021. With use of a linked dat"],"journal":["JAMA network open"],"pagination":["e223461"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8941351"],"repository":["biostudies-literature"],"pubmed_title":["Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults."],"pmcid":["PMC8941351"],"pubmed_authors":["Sampson JN","Dores GM","Chanock SJ","Morton LM","Shiels MS","Schonfeld SJ","Engels EA","Tucker MA"],"additional_accession":[]},"is_claimable":false,"name":"Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.","description":"<h4>Importance</h4>Immune checkpoint inhibitors (ICIs) have improved survival in patients with advanced melanoma but can be associated with a spectrum of immune-related adverse events (AEs), including both autoimmune-related AEs and other immune-related inflammatory AEs. These associations have primarily been evaluated in clinical trials that include highly selected patients, with older adults often underrepresented.<h4>Objective</h4>To evaluate the association between use of ICIs and immune-related AEs (autoimmune and other immune related) among older patients with cutaneous melanoma.<h4>Design, setting, and participants</h4>A population-based cohort study was conducted from January 1, 2011, to December 31, 2015. Data were analyzed from January 31 to May 31, 2021. With use of a linked dat","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-04T22:17:21.375Z","creation":"2025-04-04T22:17:21.375Z"},"accession":"S-EPMC8941351","cross_references":{"pubmed":["35315916"],"doi":["10.1001/jamanetworkopen.2022.3461"]}}